Scientific publications
- [SOLID TUMOR]
- [LUNGSEARCH: LUNG CANCER SCREENING, EARLY DETECTION, BIOMARKERS AND NEW THERAPEUTIC TARGETS ]
- [CANCER DIVISION]
Defining a Correlative Transcriptional Signature Associated with Bulk Histone H3 Acetylation Levels in Adult Glioblastomas. Scientific Publication
Irati Hervás-Corpión 1 2, Jorge Navarro-Calvo 3, Paula Martín-Climent 3, Marianela Iriarte-Gahete 4, Noelia Geribaldi-Doldán 5, Carmen Castro 5, Luis M Valor 3
Abstract
Glioblastoma (GB) is the most prevalent primary brain cancer and the most aggressive form of glioma because of its poor prognosis and high recurrence. To confirm the importance of epigenetics in glioma, we explored The Cancer Gene Atlas (TCGA) database and we found that several histone/DNA modifications and chromatin remodeling factors were affected at transcriptional and genetic levels in GB compared to lower-grade gliomas.
We associated these alterations in our own cohort of study with a significant reduction in the bulk levels of acetylated lysines 9 and 14 of histone H3 in high-grade compared to low-grade tumors. Within GB, we performed an RNA-seq analysis between samples exhibiting the lowest and highest levels of acetylated H3 in the cohort; these results are in general concordance with the transcriptional changes obtained after histone deacetylase (HDAC) inhibition of GB-derived cultures that affected relevant genes in glioma biology and treatment (e.g., A2ML1, CD83, SLC17A7, TNFSF18).
Overall, we identified a transcriptional signature linked to histone acetylation that was potentially associated with good prognosis, i.e., high overall survival and low rate of somatic mutations in epigenetically related genes in GB. Our study identifies lysine acetylation as a key defective histone modification in adult high-grade glioma, and offers novel insights regarding the use of HDAC inhibitors in therapy.
CITATION Cells. 2023 Jan 19;12(3):374. doi: 10.3390/cells12030374.
![](/.resources/ModuloCUN/resources/img/publicaciones/icono-destacado-investigadores.png)
Our authors
![Irati Hervás. Investigadora del grupo Terapias Avanzadas para Tumores Sólidos Pediátricos. Cima Universidad de Navarra](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/investigadores/hervas-irati/jcr:content/hervas-irati.jpg)